Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315709547> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4315709547 endingPage "e453" @default.
- W4315709547 startingPage "e453" @default.
- W4315709547 abstract "Objective: Cardiorenal syndrome (CRS) is the leading cause of death associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), however, the underlying mechanism of CKD-induced cardiac injury is incompletely understood. We reported that aldosterone is associated with cardiac fibrosis, and that inflammatory injury and lymphangiogenesis are involved. This pathogenic mechanism CKD-induced cardiac fibrosis still needs further investigation. Design and method: The unilateral ureteral obstruction (UUO) model was used to replicate the CRS type 4 model. Following induction of renal injury, the rats received eplerenone for 180-day. For in-vitro studies, we exposed human lymphatic endothelial cells (hLEC) to aldosterone and eplerenone. Changes in cardiac tissue related to lymphangiogenesis and inflammatory were analyzed in vivo. Changes in lymphangiogenesis, LEC phenotypic transformation and activation of mineralocorticoid receptor (MR)/ transforming growth factor (TGF)-beta/ vascular endothelial growth factor C (VEGFC) signaling axis involved in these changes were analyzed in vivo and in vitro. Results: We found that eplerenone ameliorated cardiac inflammation and fibrosis in UUO rats. Moreover, eplerenone inhibited MR activation, attenuated lyphangiogenesis and LEC phenotypic transformation, and regulated TGF-beta/CTGF/VEGFC signaling axis in vivo and in vitro. The levels of podoplanin, VEGFR-3 and VEGFC confirmed the role of lymphangiogenesis and inflammatory injury. Co-expression of LEC marker LYVE-1 and myofibroblast marker alpha-SMA validated EndMT in cardiac fibrosis. Treatment with eplerenone, clarified the role of aldosterone in UUO-induced cardiac fibrosis. Conclusions: We confirmed that eplerenone can alleviate UUO-induced cardiac fibrosis by inhibiting inflammation and lymphangiogenesis via MR/TGF-beta/VEGFC signaling axis. These findings provide an in-depth understanding of pathogenesis of UUO-induced cardiac injury and reveal novel therapeutic targets." @default.
- W4315709547 created "2023-01-12" @default.
- W4315709547 creator A5007090022 @default.
- W4315709547 creator A5018748194 @default.
- W4315709547 creator A5040493633 @default.
- W4315709547 creator A5049300446 @default.
- W4315709547 creator A5082183400 @default.
- W4315709547 creator A5087644493 @default.
- W4315709547 date "2023-01-01" @default.
- W4315709547 modified "2023-10-03" @default.
- W4315709547 title "PS-B12-1: EPLERENONE INHIBITS UUO-INDUCED LYMPHANGIOGENESIS AND CARDIAC FIBROSIS BY ATTENUATING INFLAMMATORY INJURY" @default.
- W4315709547 doi "https://doi.org/10.1097/01.hjh.0000917492.48464.e4" @default.
- W4315709547 hasPublicationYear "2023" @default.
- W4315709547 type Work @default.
- W4315709547 citedByCount "0" @default.
- W4315709547 crossrefType "journal-article" @default.
- W4315709547 hasAuthorship W4315709547A5007090022 @default.
- W4315709547 hasAuthorship W4315709547A5018748194 @default.
- W4315709547 hasAuthorship W4315709547A5040493633 @default.
- W4315709547 hasAuthorship W4315709547A5049300446 @default.
- W4315709547 hasAuthorship W4315709547A5082183400 @default.
- W4315709547 hasAuthorship W4315709547A5087644493 @default.
- W4315709547 hasBestOaLocation W43157095471 @default.
- W4315709547 hasConcept C121608353 @default.
- W4315709547 hasConcept C126322002 @default.
- W4315709547 hasConcept C134018914 @default.
- W4315709547 hasConcept C189135053 @default.
- W4315709547 hasConcept C2776636583 @default.
- W4315709547 hasConcept C2776914184 @default.
- W4315709547 hasConcept C2777420927 @default.
- W4315709547 hasConcept C2778525890 @default.
- W4315709547 hasConcept C2779013556 @default.
- W4315709547 hasConcept C2780072264 @default.
- W4315709547 hasConcept C2780559512 @default.
- W4315709547 hasConcept C502942594 @default.
- W4315709547 hasConcept C71924100 @default.
- W4315709547 hasConceptScore W4315709547C121608353 @default.
- W4315709547 hasConceptScore W4315709547C126322002 @default.
- W4315709547 hasConceptScore W4315709547C134018914 @default.
- W4315709547 hasConceptScore W4315709547C189135053 @default.
- W4315709547 hasConceptScore W4315709547C2776636583 @default.
- W4315709547 hasConceptScore W4315709547C2776914184 @default.
- W4315709547 hasConceptScore W4315709547C2777420927 @default.
- W4315709547 hasConceptScore W4315709547C2778525890 @default.
- W4315709547 hasConceptScore W4315709547C2779013556 @default.
- W4315709547 hasConceptScore W4315709547C2780072264 @default.
- W4315709547 hasConceptScore W4315709547C2780559512 @default.
- W4315709547 hasConceptScore W4315709547C502942594 @default.
- W4315709547 hasConceptScore W4315709547C71924100 @default.
- W4315709547 hasIssue "Suppl 1" @default.
- W4315709547 hasLocation W43157095471 @default.
- W4315709547 hasLocation W43157095472 @default.
- W4315709547 hasOpenAccess W4315709547 @default.
- W4315709547 hasPrimaryLocation W43157095471 @default.
- W4315709547 hasRelatedWork W2023418293 @default.
- W4315709547 hasRelatedWork W2037408526 @default.
- W4315709547 hasRelatedWork W2312942238 @default.
- W4315709547 hasRelatedWork W2322243425 @default.
- W4315709547 hasRelatedWork W2516746587 @default.
- W4315709547 hasRelatedWork W2530319271 @default.
- W4315709547 hasRelatedWork W2607356200 @default.
- W4315709547 hasRelatedWork W32200126 @default.
- W4315709547 hasRelatedWork W4223653734 @default.
- W4315709547 hasRelatedWork W4232426836 @default.
- W4315709547 hasVolume "41" @default.
- W4315709547 isParatext "false" @default.
- W4315709547 isRetracted "false" @default.
- W4315709547 workType "article" @default.